Pharmacological inhibition of the chemokine CXCL16 diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Wehr, Alexander ^a   Baeck, Christer ^a   Ulmer, Florian ^a   Gassler, Nikolaus ^a   Hittatiya, Kanishka ^b   Luedde, Tom ^a   Neumann, Ulf Peter ^a   Trautwein, Christian ^a   Tacke, Frank ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA CXCL16 MONOCLONAL ANTIBODY; CARBON TETRACHLORIDE; CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR6; CHOLINE; CXCL16 CHEMOKINE; CXCL16 MONOCLONAL ANTIBODY; FAT DROPLET; METHIONINE; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; SERUM ALBUMIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ALPHA CHEMOKINE; CXCL16 PROTEIN, HUMAN; CXCL16 PROTEIN, MOUSE; GRANULOCYTE CHEMOTACTIC PROTEIN 2; SCAVENGER RECEPTOR;

ACUTE LIVER FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BARIATRIC SURGERY; CELL INFILTRATION; CHRONIC LIVER FAILURE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CXCR6 GENE; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; FATTY LIVER; GENE; GENE EXPRESSION; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOGENESIS; IN VIVO STUDY; INFLAMMATION; LIVER CELL; MACROPHAGE; MALE; METHIONINE CHOLINE DEFICIENCY; METHIONINE CHOLINE DIET; MONOTHERAPY; MOUSE; NATURAL KILLER T CELL; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRITIONAL DEFICIENCY; PROTEIN EXPRESSION; PROTEIN TARGETING; SCORING SYSTEM; SERODIAGNOSIS; TREATMENT DURATION; UPREGULATION; ANIMAL; BIOSYNTHESIS; CHRONIC DISEASE; FEMALE; INTOXICATION; LIVER; METABOLISM; PATHOLOGY;

ANIMALS; CARBON TETRACHLORIDE POISONING; CHEMOKINE CXCL6; CHEMOKINES, CXC; CHRONIC DISEASE; FEMALE; HEPATOCYTES; HUMANS; LIVER; MACROPHAGES; MALE; MICE; NON-ALCOHOLIC FATTY LIVER DISEASE; RECEPTORS, SCAVENGER; UP-REGULATION;

EID: 84910020145     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112327     Document Type: Article

References (44)

1. Schuppan D, Schattenberg JM (2013) Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol 28 Suppl 1: 68-76.
2. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F (2013) The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 58: 593-608.
3. Bhala N, Jouness RI, Bugianesi E (2013) Epidemiology and natural history of patients with NAFLD. Curr Pharm Des 19: 5169-5176.
4. Jepsen P, Vilstrup H, Mellemkjaer L, Thulstrup AM, Olsen JH, et al. (2003) rognosis of patients with a diagnosis of fatty liver-a registry-based cohort study. Hepatogastroenterology 50: 2101-2104.
5. Agopian VG, Kaldas FM, Hong JC, Whittaker M, Holt C, et al. (2012) Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. Ann Surg 256: 624-633.
6. Marra F, Lotersztajn S (2013) Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des 19: 5250-5269.
7. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH (2009) Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 51: 371-379.
8. Marra F, Tacke F (2014) Roles for Chemokines in Liver Disease. Gastroenterology 147: 577-594 e571.
9. Wehr A, Baeck C, Heymann F, Niemietz PM, Hammerich L, et al. (2013) hemokine receptor CXCR6-dependent hepatic NK T Cell accumulation promotes inflammation and liver fibrosis. J Immunol 190: 5226-5236.
10. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L (2004) KT cells: what's in a name? Nat Rev Immunol 4: 231-237.
11. Tuncer C, Oo YH, Murphy N, Adams DH, Lalor PF (2013) The regulation of T-cell recruitment to the human liver during acute liver failure. Liver Int 33: 852-863.
12. Boisvert J, Kunkel EJ, Campbell JJ, Keeffe EB, Butcher EC, et al. (2003) Liverinfiltrating lymphocytes in end-stage hepatitis C virus: subsets, activation status, and chemokine receptor phenotypes. J Hepatol 38: 67-75.
13. + NKT cells patrolling liver sinusoids. PLoS Biol 3: e113.
14. Zimmermann HW, Seidler S, Nattermann J, Gassler N, Hellerbrand C, et al. (2010) Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One 5: e11049.
15. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) esign and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321.
16. Mattes MJ (1987) Biodistribution of antibodies after intraperitoneal or intravenous injection and effect of carbohydrate modifications. J Natl Cancer Inst 79: 855-863.
17. Wahl RL, Barrett J, Geatti O, Liebert M, Wilson BS, et al. (1988) The intraperitoneal delivery of radiolabeled monoclonal antibodies: studies on the regional delivery advantage. Cancer Immunol Immunother 26: 187-201.
18. Yoshida K, Fujikawa T, Yoshizawa G, Tanabea A, Sakurai K (1992) iodistribution of radiolabeled monoclonal antibody after intraperitoneal administration in nude mice with hepatic metastasis from human colon cancer. Surg Today 22: 155-158.
19. Barrett JS, Wagner JG, Fisher SJ, Wahl RL (1991) Effect of intraperitoneal injection volume and antibody protein dose on the pharmacokinetics of intraperitoneally administered IgG2a kappa murine monoclonal antibody in the rat. Cancer Res 51: 3434-3444.
20. Malato Y, Sander LE, Liedtke C, Al-Masaoudi M, Tacke F, et al. (2008) Hepatocyte-specific inhibitor-of-kappaB-kinase deletion triggers the innate immune response and promotes earlier cell proliferation during liver regeneration. Hepatology 47: 2036-2050.
21. Zimmermann HW, Tacke F (2011) Modification of chemokine pathways and immune cell infiltration as a novel therapeutic approach in liver inflammation and fibrosis. Inflamm Allergy Drug Targets 10: 509-536.
22. Hammerich L, Bangen JM, Govaere O, Zimmermann HW, Gassler N, et al. (2014) Chemokine receptor CCR6-dependent accumulation of gammadelta Tcells in injured liver restricts hepatic inflammation and fibrosis. Hepatology 59: 630-42.
23. + monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 50: 261-274.
24. Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, et al. (2011) istopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch 458: 511-523.
25. Baeck C, Wehr A, Karlmark KR, Heymann F, Vucur M, et al. (2012) harmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 61: 416-426.
26. Park O, Jeong WI, Wang L, Wang H, Lian ZX, et al. (2009) Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. Hepatology 49: 1683-1694.
27. Baffy G, Brunt EM, Caldwell SH (2012) Hepatocellular carcinoma in nonalcoholic fatty liver disease: an emerging menace. J Hepatol 56: 1384-1391.
28. Germanov E, Veinotte L, Cullen R, Chamberlain E, Butcher EC, et al. (2008) ritical role for the chemokine receptor CXCR6 in homeostasis and activation of CD1d-restricted NKT cells. J Immunol 181: 81-91.
29. Bendelac A, Savage PB, Teyton L (2007) The biology of NKT cells. Annu Rev Immunol 25: 297-336.
30. Shimaoka T, Seino K, Kume N, Minami M, Nishime C, et al. (2007) Critical role for CXC chemokine ligand 16 (SR-PSOX) in Th1 response mediated by NKT cells. J Immunol 179: 8172-8179.
31. Xu HB, Gong YP, Cheng J, Chu YW, Xiong SD (2005) CXCL16 participates in pathogenesis of immunological liver injury by regulating T lymphocyte infiltration in liver tissue. World J Gastroenterol 11: 4979-4985.
32. Uza N, Nakase H, Yamamoto S, Yoshino T, Takeda Y, et al. (2011) SR-PSOX/ CXCL16 plays a critical role in the progression of colonic inflammation. Gut 60: 1494-1505.
33. Galastri S, Zamara E, Milani S, Novo E, Provenzano A, et al. (2012) Lack of CC chemokine ligand 2 differentially affects inflammation and fibrosis according to the genetic background in a murine model of steatohepatitis. Clin Sci (Lond) 123: 459-471.
34. Syn WK, Agboola KM, Swiderska M, Michelotti GA, Liaskou E, et al. (2012) NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. Gut 61: 1323-1329.
35. Ishikawa S, Ikejima K, Yamagata H, Aoyama T, Kon K, et al. (2011) CD1drestricted natural killer T cells contribute to hepatic inflammation and fibrogenesis in mice. J Hepatol 54: 1195-1204.
36. Jin Z, Sun R, Wei H, Gao X, Chen Y, et al. (2011) Accelerated liver fibrosis in hepatitis B virus transgenic mice: involvement of natural killer T cells. Hepatology 53: 219-229.
37. Syn WK, Oo YH, Pereira TA, Karaca GF, Jung Y, et al. (2010) Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology 51: 1998-2007.
38. Wang H, Feng D, Park O, Yin S, Gao B (2013) Invariant NKT cell activation induces neutrophil accumulation and hepatitis: Oppositely regulated by IL-4 and IFN-gamma. Hepatology.
39. Gutwein P, Abdel-Bakky MS, Schramme A, Doberstein K, Kampfer-Kolb N, et al. (2009) CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein. Am J Pathol 174: 2061-2072.
40. Gutwein P, Abdel-Bakky MS, Doberstein K, Schramme A, Beckmann J, et al. (2009) CXCL16 and oxLDL are induced in the onset of diabetic nephropathy. J Cell Mol Med 13: 3809-3825.
41. + lymphocyte recruitment in vitro and in vivo. J Cell Mol Med 12: 1700-1709.
42. Mederacke I (2013) Liver fibrosis - mouse models and relevance in human liver diseases. Z Gastroenterol 51: 55-62.
43. Tacke F (2012) Functional role of intrahepatic monocyte subsets for the progression of liver inflammation and liver fibrosis in vivo. Fibrogenesis Tissue Repair 5 Suppl 1: S27.
44. Sato A, Nakashima H, Nakashima M, Ikarashi M, Nishiyama K, et al. (2014) Involvement of the TNF and FasL produced by CD11b Kupffer cells/ macrophages in CCl4-induced acute hepatic injury. PLoS One 9: e92515.